526 research outputs found
An Update on the Phenotype, Genotype and Neurobiology of ADCY5-Related Disease.
Adenylyl cyclase 5 (ADCY5)-related phenotypes comprise an expanding disease continuum, but much remains to be understood about the underlying pathogenic mechanisms of the disease. ADCY5-related disease comprises a spectrum of hyperkinetic disorders involving chorea, myoclonus, and/or dystonia, often with paroxysmal exacerbations. Hypotonia, developmental delay, and intellectual disability may be present. The causative gene encodes adenylyl cyclase, the enzyme responsible for the conversion of adenosine triphosphate (ATP) to cyclic adenosine-3',5'-monophosphate (cAMP). cAMP is a second messenger that exerts a wide variety of effects via several intracellular signaling pathways. ADCY5 is the most commonly expressed isoform of adenylyl cyclase in medium spiny neurons (MSNs) of the striatum, and it integrates and controls dopaminergic signaling. Through cAMP pathway, ADCY5 is a key regulator of the cortical and thalamic signaling that control initiation of voluntary movements and prevention of involuntary movements. Gain-of-function mutations in ADCY5 have been recently linked to a rare genetic disorder called ADCY5-related dyskinesia, where dysregulation of the cAMP pathway leads to reduced inhibitory activity and involuntary hyperkinetic movements. Here, we present an update on the neurobiology of ADCY5, together with a detailed overview of the reported clinical phenotypes and genotypes. Although a range of therapeutic approaches has been trialed, there are currently no disease-modifying treatments. Improved in vitro and in vivo laboratory models will no doubt increase our understanding of the pathogenesis of this rare genetic movement disorder, which will improve diagnosis, and also facilitate the development of precision medicine approaches for this, and other forms of hyperkinesia
Structural Analysis of Pathogenic Missense Mutations in GABRA2 and Identification of a Novel de Novo Variant in the Desensitization Gate
Background: Cys-loop receptors control neuronal excitability in the brain and their dysfunction results in numerous neurological disorders. Recently, six missense variants in GABRA2, a member of this family, have been associated with early infantile epileptic encephalopathy (EIEE). We identified a novel de novo missense variant in GABRA2 in a patient with EIEE and performed protein structural analysis of the seven variants.
Methods: The novel variant was identified by trio whole-genome sequencing. We performed protein structural analysis of the seven variants, and compared them to previously reported pathogenic mutations at equivalent positions in other Cys-loop receptors. Additionally, we studied the distribution of disease-associated variants in the transmembrane helices of these proteins.
Results: The seven variants are in the transmembrane domain, either close to the desensitization gate, the activation gate, or in inter-subunit interfaces. Six of them have pathogenic mutations at equivalent positions in other Cys-loop receptors, emphasizing the importance of these residues. Also, pathogenic mutations are more common in the pore-lining helix, consistent with this region being highly constrained for variation in control populations.
Conclusion: Our study reports a novel pathogenic variant in GABRA2, characterizes the regions where pathogenic mutations are in the transmembrane helices, and underscores the value of considering sequence, evolutionary, and structural information as a strategy for variant interpretation of novel missense mutations.info:eu-repo/semantics/publishedVersio
Minimal Mass Matrices for Dirac Neutrinos
We consider the possibility of neutrinos being Dirac particles and study
minimal mass matrices with as much zero entries as possible. We find that up to
5 zero entries are allowed. Those matrices predict one vanishing mass state, CP
conservation and U_{e3} either zero or proportional to R, where R is the ratio
of the solar and atmospheric \Delta m^2. Matrices containing 4 zeros can be
classified in categories predicting U_{e3} = 0, U_{e3} \neq 0 but no CP
violation or |U_{e3}| \neq 0 and possible CP violation. Some cases allow to set
constraints on the neutrino masses. The characteristic value of U_{e3} capable
of distinguishing some of the cases with non-trivial phenomenological
consequences is about R/2 \sin 2 \theta_{12}. Matrices containing 3 and less
zero entries imply (with a few exceptions) no correlation for the observables.
We outline models leading to the textures based on the Froggatt-Nielsen
mechanism or the non-Abelian discrete symmetry D_4 \times Z_2.Comment: 32 pages, 3 figures. Comments and references added. To appear in JHE
Searching for Secluded Dark Matter via Direct Detection of Recoiling Nuclei as well as Low Energy Electrons
Motivated by recent cosmic ray experimental results there has been a
proposition for a scenario where a secluded dark matter particle annihilates,
primarily, into Standard Model leptons through a low mass mediator particle. We
consider several varieties of this scenario depending on the type of mixing
among gauge bosons and we study the implications in novel direct dark matter
experiments for detecting low energy recoiling electrons. We find significant
event rates and time modulation effects, especially in the case where the
mediator is massless, that may be complementary to those from recoiling nuclei.Comment: 27 pages, references added, published versio
Aromatic L-amino acid decarboxylase deficiency: a patient-derived neuronal model for precision therapies
Aromatic L-amino acid decarboxylase (AADC) deficiency is a complex inherited neurological disorder of monoamine synthesis which results in dopamine and serotonin deficiency. The majority of affected individuals have variable, though often severe cognitive and motor delay, with a complex movement disorder and high risk of premature mortality. For most, standard pharmacological treatment provides only limited clinical benefit. Promising gene therapy approaches are emerging, though may not be either suitable or easily accessible for all patients. In order to better characterize the underlying disease pathophysiology and guide precision therapies, we generated a patient-derived midbrain dopaminergic (mDA) neuronal model of AADC deficiency from induced pluripotent stem cells (iPSCs). The neuronal model recapitulates key disease features, including absent AADC enzyme activity and dysregulated dopamine metabolism. We observed developmental defects affecting synaptic maturation and neuronal electrical properties, which were improved by lentiviral gene therapy. Bioinformatic and biochemical analyses on recombinant AADC predicted that the activity of one variant could be improved by L-3,4-dihydroxyphenylalanine (L-DOPA) administration; this hypothesis was corroborated in the patient-derived neuronal model, where L-DOPA treatment leads to amelioration of dopamine metabolites. Our study has shown that patient-derived disease modelling provides further insight into the neurodevelopmental sequelae of AADC deficiency, as well as a robust platform to investigate and develop personalised therapeutic approaches
Observations of the Askaryan Effect in Ice
We report on the first observations of the Askaryan effect in ice: coherent impulsive radio Cherenkov radiation from the charge asymmetry in an electromagnetic (EM) shower. Such radiation has been observed in silica sand and rock salt, but this is the first direct observation from an EM shower in ice. These measurements are important since the majority of experiments to date that rely on the effect for ultra-high energy neutrino detection are being performed using ice as the target medium. As part of the complete validation process for the Antarctic Impulsive Transient Antenna (ANITA) experiment, we performed an experiment at the Stanford Linear Accelerator Center (SLAC) in June 2006 using a 7.5 metric ton ice target, yielding results fully consistent with theoretical expectations
Aromatic l-amino acid decarboxylase deficiency: a patient-derived neuronal model for precision therapies
Aromatic l-amino acid decarboxylase (AADC) deficiency is a complex inherited neurological disorder of monoamine synthesis which results in dopamine and serotonin deficiency. The majority of affected individuals have variable, though often severe cognitive and motor delay, with a complex movement disorder and high risk of premature mortality. For most, standard pharmacological treatment provides only limited clinical benefit. Promising gene therapy approaches are emerging, though may not be either suitable or easily accessible for all patients. To characterize the underlying disease pathophysiology and guide precision therapies, we generated a patient-derived midbrain dopaminergic neuronal model of AADC deficiency from induced pluripotent stem cells. The neuronal model recapitulates key disease features, including absent AADC enzyme activity and dysregulated dopamine metabolism. We observed developmental defects affecting synaptic maturation and neuronal electrical properties, which were improved by lentiviral gene therapy. Bioinformatic and biochemical analyses on recombinant AADC predicted that the activity of one variant could be improved by l-3,4-dihydroxyphenylalanine (l-DOPA) administration; this hypothesis was corroborated in the patient-derived neuronal model, where l-DOPA treatment leads to amelioration of dopamine metabolites. Our study has shown that patient-derived disease modelling provides further insight into the neurodevelopmental sequelae of AADC deficiency, as well as a robust platform to investigate and develop personalized therapeutic approaches
Clinical Phenotype in Individuals With Birk-Landau-Perez Syndrome Associated With Biallelic SLC30A9 Pathogenic Variants
BACKGROUND AND OBJECTIVES: Birk-Landau-Perez syndrome is a genetic disorder caused by biallelic pathogenic variants in SLC30A9 presenting with a complex movement disorder, developmental regression, oculomotor abnormalities, and renal impairment. It has previously been reported in 2 families. We describe the clinical phenotype of 8 further individuals from 4 unrelated families with SLC30A9-related disease. METHOD: Following detailed clinical phenotyping, 1 family underwent research whole-genome sequencing (WGS), 1 research whole-exome sequencing, and 2 diagnostic WGS. Variants of interest were assessed for pathogenicity using in silico prediction tools, homology modeling, and, where relevant, sequencing of complementary DNA (cDNA) for splicing effect. RESULTS: In 2 unrelated families of Pakistani origin (1 consanguineous and 1 not), the same homozygous missense variant in SLC30A9 (c.1253G>T, p.Gly418Val) was identified. Family 1 included 2 affected brothers, and family 2 one affected boy. In family 3, also consanguineous, there were 4 affected siblings homozygous for the variant c.1049delCAG, pAla350del. The fourth family was nonconsanguineous: the 1 affected individual was compound heterozygous for c.1083dup, p.Val362Cysfs*5, and c.1413A>G, p.Ser471=. Despite phenotypic variability between the 4 families, all affected patients manifested with a progressive hyperkinetic movement disorder, associated with oculomotor apraxia and ptosis. None had evidence of severe renal impairment. For the novel missense variant, the conformation of the loop domain and packing of transmembrane helices are likely to be disrupted based on structure modeling. Its presence in 2 unrelated Pakistani families suggests a possible founder variant. For the synonymous variant p.Ser471=, an effect on splicing was confirmed through cDNA analysis. DISCUSSION: Pathogenic variants in SLC30A9 cause a progressive autosomal recessive neurologic syndrome associated with a complex hyperkinetic movement disorder. Our report highlights the expanding disease phenotype, which can present with a wider spectrum of severity than has previously been recognized
Parameters in a Class of Leptophilic Dark Matter Models from PAMELA, ATIC and FERMI
In this work we study a class of leptophilic dark matter models, where the
dark matter interacts with the standard model particles via the
gauge boson, to explain the excess in cosmic rays
observed by ATIC and PAMELA experiments, and more recently by Fermi experiment.
There are three types of models: a) , b)
, and c) . Although ATIC or Fermi
data is consistent with PAMELA data separately, ATIC and Fermi data do not
agree with each other. We therefore aim to identify which of the three models
can explain which data set better. We find that models a) and b) can give
correct dark matter relic density and explain the ATIC and PAMELA data
simultaneously recur to the Breit-Wigner enhancement. Whereas model c) with a
larger mass can explain Fermi and PAMELA data simultaneously. In all
cases the model parameters are restricted to narrow regions. Future improved
data will decide which set of data are correct and also help to decide the
correct dark matter model.Comment: Latex 15 pages with 5 figures. Modified to include discussions of
recent Fermi data on the leptophilic models studied in this paper. Title also
modifie
New Limits on the Ultra-high Energy Cosmic Neutrino Flux from the ANITA Experiment
We report initial results of the first flight of the Antarctic Impulsive
Transient Antenna (ANITA-1) 2006-2007 Long Duration Balloon flight, which
searched for evidence of a diffuse flux of cosmic neutrinos above energies of 3
EeV. ANITA-1 flew for 35 days looking for radio impulses due to the Askaryan
effect in neutrino-induced electromagnetic showers within the Antarctic ice
sheets. We report here on our initial analysis, which was performed as a blind
search of the data. No neutrino candidates are seen, with no detected physics
background. We set model-independent limits based on this result. Upper limits
derived from our analysis rule out the highest cosmogenic neutrino models. In a
background horizontal-polarization channel, we also detect six events
consistent with radio impulses from ultra-high energy extensive air showers.Comment: 4 pages, 2 table
- …